Variable Performance of D-dimer Testing by Hemostasis Laboratories: The Australasian/Asia-Pacific Experience

Abstract D-dimers represent the breakdown products of fibrin. Thus, elevated plasma D-dimers will arise following a thrombotic event, such as a deep vein thrombosis or a pulmonary embolism, and therefore, a nonelevated D-dimer is used to effectively exclude such events. D-dimers are also elevated in a range of other conditions, for example, during disseminated intravascular coagulation. D-dimer levels may also be associated with prognostic value. For example, highly raised D-dimer levels can be associated with worsening clinical features in coronavirus disease 2019. Thus, D-dimer testing represents a commonly requested hemostasis test, often performed in 24/7 laboratories. Unfortunately, D-dimer testing is neither standardized nor harmonized across manufacturers or laboratories. Indeed, considering reporting units and the magnitude of units, up to 28 different combinations may be reported by laboratories. We provide updated findings for D-dimer testing in our geographic region, using recent data from the Royal College of Pathologists of Australasia Quality Assurance Programs, an international external quality assessment program, currently with over 450 participants in the D-dimer module. Data show a wide variety of assays in use and variable outcomes in reported numerical values when assessing proficiency samples. D-dimer testing mostly comprised reagents from three main manufacturing suppliers, with a small number of users of reagents from other manufacturers. Reported results showed important differences in numerical values for the same homogeneous tested samples when normalized to a single reporting unit (e.g., mg/L). Nevertheless, despite using different test reagents and reporting, most participants uniformly identified D-dimer values as below or above a “detection” cut-off for samples that were constructed to be below or above most cut-off values. As expected, mixed findings were reported for samples containing levels around expected cut-off values. We hope that our findings, reflecting on the heterogeneity of test reagents and test data, help improve diagnostic testing for D-dimer testing and facilitate harmonization and standardization, in the future.

[1]  E. Favaloro,et al.  D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap , 2024, Research and practice in thrombosis and haemostasis.

[2]  G. Kershaw,et al.  Assessment of immunological anti‐platelet factor 4 antibodies for vaccine‐induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients , 2022, Journal of Thrombosis and Haemostasis.

[3]  G. Lippi,et al.  D-dimers-"Normal" Levels versus Elevated Levels Due to a Range of Conditions, Including "D-dimeritis," Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. , 2022, Seminars in thrombosis and hemostasis.

[4]  E. Favaloro,et al.  Pathology utilisation during COVID-19 outbreaks beyond viral testing: routine coagulation and D-dimer testing , 2022, Pathology.

[5]  M. D. de Maat,et al.  Impact of COVID‐19 pandemic on the quality of test output in haemostasis laboratories , 2021, International journal of laboratory hematology.

[6]  G. Lippi,et al.  Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT) , 2021, Clinical chemistry and laboratory medicine.

[7]  C. Longstaff,et al.  Is it possible to make a common reference standard for D‐dimer measurements? Communication from the ISTH SSC Subcommittee on Fibrinolysis , 2021, Journal of thrombosis and haemostasis : JTH.

[8]  E. Favaloro,et al.  Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study) , 2021, Journal of Thrombosis and Thrombolysis.

[9]  E. Favaloro,et al.  Variability in D-dimer reporting revisited , 2020, Pathology.

[10]  G. Lippi,et al.  D-dimer measurement in COVID-19: Silver bullet or clinical distraction? , 2020, Thrombosis Research.

[11]  J. Thachil,et al.  Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation , 2020, Clinical chemistry and laboratory medicine.

[12]  Kristi J Smock,et al.  What have we learned from coagulation laboratory participation in external quality programs? , 2019, International journal of laboratory hematology.

[13]  Susan Louw,et al.  A pilot study to introduce a local external quality assurance scheme for D‐dimers in the National Health Laboratory Service, in South Africa , 2019, International journal of laboratory hematology.

[14]  A. Šimundić,et al.  International Survey on D-Dimer Test Reporting: A Call for Standardization , 2015, Seminars in Thrombosis & Hemostasis.

[15]  C. Eby,et al.  D-dimer: simple test, tough problems. , 2013, Archives of pathology & laboratory medicine.

[16]  M. Crowther,et al.  Human-derived D-dimer for external quality assessment: results of four surveys in Ontario. , 2008, American journal of clinical pathology.

[17]  E. Favaloro Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations. , 2007, Seminars in thrombosis and hemostasis.

[18]  S. Kitchen,et al.  Emerging Technologies and Quality Assurance: The United Kingdom National External Quality Assessment Scheme Perspective , 2007, Seminars in thrombosis and hemostasis.

[19]  A. Tripodi,et al.  Performance of quantitative D‐dimer methods: results of the Italian external quality assessment scheme , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  B. Verbruggen,et al.  A model for the harmonisation of test results of different quantitative D-dimer methods , 2006, Thrombosis and Haemostasis.

[21]  H. Reinauer,et al.  The performance of quantitative D-dimer assays in laboratory routine , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  G. Lippi,et al.  Harmonisation of D-dimer - A call for action. , 2016, Thrombosis research.

[23]  P. Moerloose,et al.  Quantitative D-dimer for the Exclusion of Venous Thromboembolic Disease; Approved Guideline H59-A , 2011 .

[24]  K. Matsuno,et al.  Quality control and quality assessment of coagulation tests in Japan. , 2002, The Southeast Asian journal of tropical medicine and public health.

[25]  Cornelis Kluft1,et al.  Performance of Semiquantitative and Quantitative D-Dimer Assays in the ECAT External Quality Assessment Program , 2000 .